Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Lands Distribution Rights to Taliaz Antidepressant Drug Selection Tools

NEW YORK — Genetic Technologies said on Wednesday that it has acquired the distribution rights to Taliaz's Predictix line of antidepressant drug selection tools in Australia, New Zealand, and the US.

According to Taliaz, the products analyze various datasets including a patient's genetic and metabolic profiles, clinical history, and demographics to inform prescribing decisions. The Tel Aviv, Israel-based company currently offers Predictix Digital, which focuses on clinical and demographic data, and Predictix Genetics, which uses genetic testing data.

Under the terms of the deal, Melbourne-based Genetic Technologies will have the exclusive distribution rights to the products in Australia and New Zealand, and nonexclusive distribution rights in the US, over a three-year period.

Genetic Technologies said that pending regulatory clearance in the three markets it has committed to a minimum distribution of 8,000 Predictix tests over the term of the agreement with an associated minimum cost of A$200,000 (US$147,744), including licensing fees and a percentage based fee per test paid to Taliaz.

Genetic Technologies said it expects to launch the products in Australia and New Zealand in the third quarter of next year.

"This distribution agreement is our first external product partnership and our first product within the mental health vertical," Genetic Technologies Interim CEO George Muchnicki said in a statement. The company, which offers genetic risk assessment tests for breast and colorectal cancer, added that the deal represents its first move into the pharmacogenomics field.

Taliaz expects to expand the Predictix products to cover additional mental health conditions in the future.